Kyowa Kirin to offload nartograstim to settle antimonopoly concerns
This article was originally published in Scrip
Executive Summary
Kyowa Hakko Kirin is to transfer all Japanese rights to its recombinant granulocyte colony stimulating factor (G-CSF) Neu-up (nartograstim) to fellow Japanese company Yakult Honsha next spring, in a move to resolve antimonopoly concerns.